Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,755 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Major Depressive Disorders Clear all
Completed Phase 3 Interventional

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

NCT00252356
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SR58611A
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 28, 2026, 5:41 PM EDT
Not yet recruiting Not applicable Interventional

Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation

NCT07842601
View directory record Official record
Conditions
Opioid Use Disorder, Major Depressive Disorder (MDD)
Interventions
Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Treat Major Depressive Disorder With a New Medication

NCT03043560
View directory record Official record
Conditions
Depressive Disorder, Anhedonia
Interventions
Ezogabine, Placebos
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dopaminergic Dysfunction in Late-Life Depression

NCT04469959
View directory record Official record
Conditions
Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Interventions
L-Dopa, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 28, 2026, 5:41 PM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 28, 2026, 5:41 PM EDT
Completed No phase listed Observational Results available

Treatment-Resistant Depression Registry

NCT00320372
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
55
States / cities
Tucson, Arizona • Beverly Hills, California • Garden Grove, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01309945
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Placebo matching with BMS-820836, BMS-820836, Placebo matching with Duloxetine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Little Rock, Arkansas • Arcadia, California • Encino, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Not applicable Interventional

Storytelling Video Intervention for Depressed Primary Care Patients - Pilot Trial

NCT02311725
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
aTAU + sTVi, aTAU + Attention Control Videos
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Not applicable Interventional

Financial Incentives to Improve Medication Adherence

NCT04191876
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions
Wellth - Financial Incentives
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions
NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 28, 2026, 5:41 PM EDT
Recruiting Phase 2 Interventional

5-HTP and Creatine for Depression R33 Phase

NCT05895747
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate, High Dose Creatine Monohydrate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 5:41 PM EDT
Completed No phase listed Observational

Implementation of Harmonized Depression Outcome Measures in a Primary Care Registry and a Mental Health Registry

NCT04235725
View directory record Official record
Conditions
Major Depression, Dysthymia
Interventions
Harmonized Depression Outcome Measures
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 28, 2026, 5:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

NCT01098240
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CP-601,927, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
58
States / cities
Little Rock, Arkansas • Beverly Hills, California • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group

NCT00265291
View directory record Official record
Conditions
Major Depressive Disorder, Major Depression, Unipolar Depression
Interventions
fluoxetine or desipramine
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2008 · Synced Oct 28, 2026, 5:41 PM EDT
Withdrawn Phase 3 Interventional

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

NCT02212613
View directory record Official record
Conditions
Major Depressive Disorder and Irritability
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Relapse & Recurrence of Bipolar Depression

NCT00961961
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium / Fluoxetine, Lithium / Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

NCT06126497
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ropanicant
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Bellflower, California • Orange, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 5:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Biological Markers for Severe Depression

NCT01831882
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
3
States / cities
Irvine, California • Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 28, 2026, 5:41 PM EDT
Recruiting Phase 3 Interventional

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
46
States / cities
Huntsville, Alabama • Bryant, Arkansas • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 2 Interventional

A Study of Intermittent Doses of CERC-301 in MDD

NCT02459236
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CERC-301, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Newport Beach, California • Alpharetta, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ESTIA: Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults

NCT02891564
View directory record Official record
Conditions
Major Depression
Interventions
Band Together, Control Mobile 3D video game
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
White Plains, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 3 Interventional

Predictors of Depression Treatment Response to Exercise

NCT02583867
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 28, 2026, 5:41 PM EDT
Completed Phase 4 Interventional Results available

Antidepressant Therapy in Treating Bipolar Type II Major Depression

NCT00602537
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
Venlafaxine, Lithium Carbonate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 28, 2026, 5:41 PM EDT